ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

医学 耐受性 无容量 内科学 肿瘤科 临床终点 肺癌 临床试验 临床研究阶段 癌症 不利影响 免疫疗法
作者
John Wrangle,Vamsidhar Velcheti,Manish R. Patel,Elizabeth Garrett‐Mayer,Elizabeth G. Hill,James G. Ravenel,Jeffrey S. Miller,Mohammad Farhad,Kate Anderton,Kathryn Lindsey,Michele Taffaro-Neskey,Carol A. Sherman,Samantha Suriano,Marzena Swiderska‐Syn,Amy Sion,Joni Harris,Andie Edwards,Julie Rytlewski,Catherine Sanders,Erik Yusko
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:19 (5): 694-704 被引量:421
标识
DOI:10.1016/s1470-2045(18)30148-7
摘要

Summary

Background

Immunotherapy with PD-1 or PD-L1 blockade fails to induce a response in about 80% of patients with unselected non-small cell lung cancer (NSCLC), and many of those who do initially respond then develop resistance to treatment. Agonists that target the shared interleukin-2 (IL-2) and IL-15Rβγ pathway have induced complete and durable responses in some cancers, but no studies have been done to assess the safety or efficacy of these agonists in combination with anti-PD-1 immunotherapy. We aimed to define the safety, tolerability, and activity of this drug combination in patients with NSCLC.

Methods

In this non-randomised, open-label, phase 1b trial, we enrolled patients (aged ≥18 years) with previously treated histologically or cytologically confirmed stage IIIB or IV NSCLC from three academic hospitals in the USA. Key eligibility criteria included measurable disease, eligibility to receive anti-PD-1 immunotherapy, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients received the anti-PD-1 monoclonal antibody nivolumab intravenously at 3 mg/kg (then 240 mg when US Food and Drug Administration [FDA]-approved dosing changed) every 14 days (either as new treatment or continued treatment at the time of disease progression) and the IL-15 superagonist ALT-803 subcutaneously once per week on weeks 1–5 of four 6-week cycles for 6 months. ALT-803 was administered at one of four escalating dose concentrations: 6, 10, 15, or 20 μg/kg. The primary endpoint was to define safety and tolerability and to establish a recommended phase 2 dose of ALT-803 in combination with nivolumab. Analyses were per-protocol and included any patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, number NCT02523469; phase 2 enrolment of patients is ongoing.

Findings

Between Jan 18, 2016, and June 28, 2017, 23 patients were enrolled and 21 were treated at four dose levels of ALT-803 in combination with nivolumab. Two patients did not receive treatment because of the development of inter-current illness during enrolment, one patient due to leucopenia and one patient due to pulmonary dysfunction. No dose-limiting toxicities were recorded and the maximum tolerated dose was not reached. The most common adverse events were injection-site reactions (in 19 [90%] of 21 patients) and flu-like symptoms (15 [71%]). The most common grade 3 adverse events, occurring in two patients each, were lymphocytopenia and fatigue. A grade 3 myocardial infarction occurred in one patient. No grade 4 or 5 adverse events were recorded. The recommended phase 2 dose of ALT-803 is 20 μg/kg given once per week subcutaneously in combination with 240 mg intravenous nivolumab every 2 weeks.

Interpretation

ALT-803 in combination with nivolumab can be safely administered in an outpatient setting. The promising clinical activity observed with the addition of ALT-803 to the regimen of patients with PD-1 monoclonal antibody relapsed and refractory disease shows evidence of anti-tumour activity for a new class of agents in NSCLC.

Funding

Altor BioScience (a NantWorks company), National Institutes of Health, and Medical University of South Carolina Hollings Cancer Center.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lmsxg完成签到,获得积分10
刚刚
刚刚
1秒前
1秒前
gaoyi12356发布了新的文献求助10
1秒前
顺问冬安发布了新的文献求助10
2秒前
减肥的蕉太狼完成签到,获得积分10
2秒前
2秒前
焦自钊完成签到,获得积分10
3秒前
4秒前
完美世界的应助被腼腆的虔纹采纳,获得10
4秒前
Akim的应助被Sicily采纳,获得10
4秒前
B1t272发布了新的文献求助10
4秒前
4秒前
5秒前
5秒前
5秒前
214发布了新的文献求助10
6秒前
思源的应助被顺问冬安采纳,获得10
6秒前
15331970326发布了新的文献求助10
6秒前
香蕉觅云的应助被Maromains采纳,获得10
6秒前
6秒前
黄毛虎发布了新的文献求助10
9秒前
晨晨发布了新的文献求助20
9秒前
9秒前
Voyager发布了新的文献求助10
9秒前
乐乐的应助被ldd采纳,获得10
9秒前
10秒前
10秒前
mmyhn发布了新的文献求助10
12秒前
缺粥发布了新的文献求助10
12秒前
12秒前
12秒前
bkagyin的应助被mmm采纳,获得10
13秒前
13秒前
顺问冬安完成签到,获得积分20
13秒前
我是老大的应助被kogense采纳,获得10
13秒前
山鸟发布了新的文献求助10
14秒前
王淼发布了新的文献求助12
14秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187480
求助须知:如何正确求助?哪些是违规求助? 9575554
关于积分的说明 21841909
捐赠科研通 7785230
什么是DOI,文献DOI怎么找? 3434949
关于科研通互助平台的介绍 2559412
邀请新用户注册赠送积分活动 2481898